Molecular Insight is led by a highly experienced and proven management team. The drug development process can be complex and Molecular Insight’s management team offers deep expertise in all aspects of the process to drive products toward commercialization.
Nelson K. Stacks
Chief Executive Officer
Nelson K. Stacks was appointed Chief Executive Officer and Director in July 2012. He joined Molecular Insight as the Interim CEO and Executive Director in December 2011. Mr. Stacks is also a Director of Wave Guide Technology, a medical diagnostic company with the first-of-its kind of hand-held Nuclear Magnetic Resonance machine to diagnose cancer and other disease states at point of care. Prior to that, Mr. Stacks was President and Chief Executive Officer of Vascular Pathways Incorporated, a medical device company focused on peripheral IV, where he raised capital from leading Venture Capital groups and brought the company through regulatory requirements and also initiated manufacturing of high-volume, complex products.
Mr. Stacks has also served as Board Chairman and Director at XBIO, as the Executive Director and CEO at Xenome Limited, and as a General Partner with the British Venture Capital firm, 3i Plc. From 2006-2008 he was the Chief Executive Officer and a Director of Telesso Technologies. Mr. Stacks started his career as a Principal/Kauffman Fellow at Oak Investment Partners. He has investor experience in all areas of healthcare and information technology, and operating experience across multiple healthcare platforms including therapeutics, devices, and services.
Mr. Stacks received his BA from the University of Rochester and his MBA from the Franklin W. Olin Graduate School of Business at Babson College.
John W. Babich, Ph.D.
President and Chief Scientific Officer
John W. Babich, Ph.D., a founder of the Company in 1997, serves as President and Chief Scientific Officer. He has led the scientific and clinical development strategies since the Company’s inception. Under Dr. Babich’s direction the Company has developed two proprietary radiochemistry platform technologies which form the basis of three clinical candidates. He has also built worldwide academic collaborations in oncology, radiation biology, radiation oncology, chemistry and radiochemistry research. He has been an active researcher in the field of molecular imaging and targeted radionuclide therapy for the past 25 years. Prior to joining the Company, he was Assistant Professor of Radiology at Harvard Medical School and Staff Radiopharmaceutical Chemist at Massachusetts General Hospital (MGH), Boston, Massachusetts. Prior to joining MGH, Dr. Babich was Principal Scientist and Head of the Radiopharmaceutical Section at the Institute of Cancer Research in England. His previous research experience includes the use of radiolabeled monoclonal antibodies in cancer imaging and therapy, radiolabeled peptides and small molecules in oncology, cardiology and infectious disease. He has also applied the use of positron emission tomography for the study of drug pharmacokinetics and pharmacodynamics in humans. He has published more than 150 research articles in a variety of peer-reviewed journals, as well as several book chapters and invited reviews. He is inventor or co-inventor of 24 issued and pending patents.
Dr. Babich has served as President of the Society of Nuclear Medicine's Radiopharmaceutical Science Council. Dr. Babich received a BS degree in pharmaceutical sciences from St. John’s University, an MS from University of Southern California, and a Doctorate from the University of London.
Vice President, Portfolio Strategy and Manufacturing
In December 2009, Wendy Graham-Coco was named Vice President of Portfolio Strategy and Manufacturing. Ms. Graham-Coco has more than 20 years of research experience, including 16 years in discovery research, of which seven were in academic drug discovery at the Massachusetts General Hospital in Boston. She has experience managing various phases of drug development, including preclinical development, early clinical development and manufacturing. Prior to her tenure as Vice President at Molecular Insight, Ms. Graham-Coco served in various roles in Program Management, Operations and Business Development.
Ms. Graham-Coco earned a BA in biology, Pre-Med at Boston University and an MBA from Simmons Graduate School of Management.
John L. Joyal, Ph.D.
Vice President of Discovery Research
John L. Joyal, Ph.D. has served as our Vice President of Discovery Research since January of 2008. He joined Molecular Insight as Director of Biology in 2005. He has over 20 years of oncology basic research and drug discovery experience with expertise in cell and molecular biology particularly in the areas of receptor biology, signal transduction pathways, and assay development.
Prior to joining Molecular Insight, Dr. Joyal was Director of Discovery Research at Phylogix Pharmaceuticals where he led a team evaluating the biology and mechanism of action of protein therapeutics for oncology supportive care. From 1997 to 2004, he held several positions at Praecis Pharmaceuticals including Director of Cell Biology, where he initiated or contributed to the establishment of numerous research projects focusing on the discovery of novel therapeutics for the treatment of cancer, inflammation, infectious disease, and neurological disorders. From 1993 to 1997, Dr. Joyal did his post-doctoral training at Harvard Medical School/Brigham and Women’s Hospital examining novel interactions between the calcium sensor, calmodulin, and proteins involved in breast carcinogenesis and growth factor signaling. He received his Doctorate in biology from Tufts University studying mitochondrial physiology.
Kevin J. Lloyd
Vice President, Development Operations
Kevin J. Lloyd joined Molecular Insight in May 2012 as Vice President, Development Operations. He has over 20 years of experience in Clinical Development, working at both large and small biopharmaceutical companies, an academic medical center, and a large Contract Research Organization (CRO) in the greater Boston area. Prior to joining Molecular Insight, Mr. Lloyd was Executive Director of Clinical Operations at ZIOPHARM Oncology, where he oversaw operations for the DNA Therapeutics franchise from ZIOPHARM's exclusive channel partnership with Intrexon Corporation.
From 2006 to 2011, Mr. Lloyd was instrumental in establishing and heading the Clinical Business Operations group at Millennium Pharmaceuticals, which included the creation and optimization of centralized clinical contract, budget, and training functions in support of Millennium's Medical Division. From 1998 to 2006, he held positions of progressive responsibility in Clinical Operations and Development at Millennium, ImmunoGen and Biogen, Inc. Previously, he worked in clinical roles at PAREXEL International Corporation and Tufts New England Medical Center. In addition to his extensive background in Clinical Development and Operations in all phases of drug development, Mr. Lloyd has strong experience in a variety of oncology therapeutic areas.
Mr. Lloyd received a BA from the University of Vermont.
James A. Wachholz
Vice President, Regulatory Affairs and Quality Assurance
James A. Wachholz has served as Vice President, Regulatory Affairs and Quality Assurance since May 2005. He has more than 20 years of experience in regulatory affairs and product development at biotechnology and pharmaceutical companies. From 2003 to May 2005, he worked at Accentia Biopharmaceuticals, where he served as Chief Regulatory Officer. From 1998 to 2003 Mr. Wachholz worked at Sepracor Inc., where he served as the Executive Director of Regulatory Affairs. Previously, Mr. Wachholz held regulatory and compliance positions at Hybridon, Inc., Searle Pharmaceuticals and Baxter International.
Mr. Wachholz received a BS in biochemistry from Northern Illinois University and an MBA from DePaul University.